Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Who Are Receiving Standard Chemotherapy Regimens.

NCT01783197 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT01783197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01783197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Who Are Receiving Standard Chemotherapy Regimens.
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 1
Overall status
Completed
Start date
June 4, 2013
Completion date
April 2, 2019
Enrollment
39 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer